InsiderPulse
Dashboard

JAZZ

Jazz Pharmaceuticals plc

Health CareRussell 2000

Jazz Pharmaceuticals plc insider trading

Jazz Pharmaceuticals plc files with the SEC as a Pharmaceutical Preparations company headquartered in Dublin. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.

From SEC filings

Recent JAZZ insider transactions

4 insiders traded JAZZ on the open market between Jul 01, 2026 and Sep 10, 2026 — 11 sales worth $24.4M, of which every one was pre-scheduled under a 10b5-1 plan.

Bought
—
Sold
$24.4M

11 of 11 on a 10b5-1 plan

Net
−$24.4M
Insiders
4

Open-market purchases (code P) and sales (code S) from Jazz Pharmaceuticals plc's own SEC Form 4 filings. Grants and option exercises are excluded — they are compensation, not decisions. Share counts are derived from the reported value and price. Verify any figure against the original filing before acting on it; this is monitoring, not advice.

Filing history last read from EDGAR on Sep 23, 2026. The live dashboard shows new filings the moment they clear.

Every JAZZ Form 4 on SEC.gov

SEC Form 4 data, Q3 2024 to Q2 2026

JAZZ insider trading by quarter

Between Jul 01, 2024 and Jun 30, 2026, 11 insiders traded JAZZ on the open market: 4 purchases worth $10M and 74 sales worth $50.8M, 29 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 53 sales ($45.3M), by 10 insiders.

QuarterBoughtSold
Q2 2026—−$7.4M11 sales · 8 on a plan
Q1 2026—−$14.2M19 sales · 3 on a plan
Q4 2025—−$22.7M18 sales · 3 on a plan
Q3 2025—−$992.5K5 sales · all on a plan
Q2 2025+$10M4 buys−$470.9K5 sales · all on a plan
Q1 2025—−$4.1M11 sales · 4 on a plan
Q4 2024—−$816.3K4 sales · 1 on a plan
Q3 2024—−$152.7K1 sale
Largest purchase
+$7.9M of JAZZ by Mulligan Seamus (Director) on May 09, 2025.
Largest sale
−$6.8M of JAZZ by Cozadd Bruce C (Director) on Nov 26, 2025.

Open-market transactions through Jun 30, 2026most recent first

  • Smith Mark Douglas10b5-1

    Director

    −$266.7K

    Jun 15, 2026

    1,157 sh · $230.55

  • Patil Neena M10b5-1

    EVP & Chief Legal Officer

    −$278.2K

    Jun 10, 2026

    1,200 sh · $231.83

  • Cozadd Bruce C10b5-1

    Director

    −$1.4M

    Jun 01, 2026

    6,000 sh · $235.12

  • Pearce Samantha

    EVP, Chief Commercial Officer

    −$1.6M

    May 28, 2026

    6,907 sh · $235.41

  • Patil Neena M10b5-1

    EVP & Chief Legal Officer

    −$282.5K

    May 28, 2026

    1,192 sh · $236.97

  • Winningham Rick E

    Director

    −$662.1K

    May 22, 2026

    2,741 sh · $241.57

  • McSharry Heather Ann

    Director

    −$482K

    May 22, 2026

    2,000 sh · $241.00

  • Cozadd Bruce C10b5-1

    Director

    −$1.2M

    May 01, 2026

    6,000 sh · $203.33

  • Cozadd Bruce C10b5-1

    Director

    −$700.8K

    Apr 01, 2026

    3,684 sh · $190.22

  • Cozadd Bruce C10b5-1

    Director

    −$437.6K

    Apr 01, 2026

    2,292 sh · $190.94

  • Cozadd Bruce C10b5-1

    Director

    −$4.6K

    Apr 01, 2026

    24 sh · $191.74

  • Carr Patricia

    SVP, Chief Accounting Officer

    −$235.4K

    Mar 09, 2026

    1,287 sh · $182.94

  • Cozadd Bruce C10b5-1

    Director

    −$587.9K

    Mar 03, 2026

    3,159 sh · $186.09

  • Cozadd Bruce C10b5-1

    Director

    −$487K

    Mar 03, 2026

    2,608 sh · $186.73

  • Cozadd Bruce C10b5-1

    Director

    −$43.8K

    Mar 03, 2026

    233 sh · $187.84

From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.

Jazz Pharmaceuticals plc company record

SEC industry classification
Pharmaceutical Preparations
Headquarters
Dublin
Incorporated in
L2
Listed on
Nasdaq
SEC Central Index Key
0001232524
Previously filed as
JAZZ PHARMACEUTICALS INC

Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.

After insiders bought JAZZ

What the stock actually did in the 90 days following each open-market purchase

Don't check JAZZ — let it ping you

Get told the moment an insider moves on JAZZ

Pro watches Jazz Pharmaceuticals plc for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add JAZZ to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.

Track JAZZ on the live dashboardFilings on SEC.gov

The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.

How to read JAZZ insider activity

Open-market purchase (code P)
An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
Grants and option exercises (codes A, M)
Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
Cluster buy
Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.

Other Health Care tickers

HALOEXASNTRACRSPNTLABEAMRXRXTWSTPACBARWRIONSAXSM
This week on the tape: who actually chose to sellThe weekly split of scheduled 10b5-1 selling vs deliberate sales, with the deciders named.

Questions

Are JAZZ insiders buying or selling?
Between Jul 01, 2026 and Sep 10, 2026, 4 Jazz Pharmaceuticals plc insiders made no open-market purchases and 11 sales worth $24.4M, a net sale of $24.4M. 11 of the sales were pre-scheduled under a Rule 10b5-1 plan.
How much JAZZ stock have insiders bought and sold in the last two years?
Between Jul 01, 2024 and Jun 30, 2026, 11 Jazz Pharmaceuticals plc insiders made 4 open-market purchases worth $10M and 74 sales worth $50.8M. 29 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 53 sales ($45.3M). The largest purchase was Mulligan Seamus buying $7.9M on May 09, 2025. The largest sale was Cozadd Bruce C selling $6.8M on Nov 26, 2025.
What was the largest recent JAZZ insider trade?
Iannone Robert (EVP, Global Head of R&D & CMO) sold $4.9M of JAZZ stock on Aug 27, 2026 at about $250.60 a share, under a pre-scheduled 10b5-1 plan.
When did an insider last buy JAZZ shares?
No open-market purchase by a Jazz Pharmaceuticals plc insider appears in the filings from Jul 01, 2026 to Sep 10, 2026 — every recorded open-market transaction in that period was a sale. Before that, the most recent purchase in SEC's data was Mulligan Seamus buying $167K on May 12, 2025.
Where does JAZZ insider trading data come from?
From the Form 4 filings Jazz Pharmaceuticals plc's officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.

Get the free Insider Brief

Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.

No account needed. One-click unsubscribe.